← All themes Genomics & Gene Editing

Gene Therapy

Gene therapy delivers a working copy of a gene, or a correction to a faulty one, usually once and for life. Manufacturing the delivery vector is often harder than designing the therapy.

131 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Novartis NVS $279B	987	-26	-3%	$19.3B
2	2 Charles River Laboratories CRL $14.4B	348	+15	+5%	$5.19B
3	3 Sarepta Therapeutics SRPT $1.78B	318	+49	+18%	$7.92B
4	4 DELISTED bluebird bio BLUE	307	+4	+1%	$8.41B
5	5 DELISTED CATALENT, INC. CTLT	262	-12	-4%	$5.63B
6	6 DELISTED SANGAMO THERAPEUTICS INC SGMO	210	+2	+1%	$919M
7	7 Regenxbio RGNX $454M	177	+57	+48%	$1.87B
8	8 CRISPR Therapeutics CRSP $4.86B	174	+39	+29%	$1.09B
9	9 Precigen PGEN $2.64B	166	0	0%	$1.53B
10	10 PTC Therapeutics PTCT $4.98B	166	+18	+12%	$1.45B
11	11 Ultragenyx Pharmaceutical RARE $1.47B	158	-7	-4%	$3.75B
12	12 Intellia Therapeutics NTLA $1.6B	156	+26	+20%	$789M
13	13 Vericel Corp VCEL $2.06B	129	+45	+54%	$317M
14	14 Voyager Therapeutics VYGR $124M	125	+17	+16%	$569M
15	15 Atara Biotherapeutics ATRA $96M	124	+10	+9%	$1.71B
16	16 Lineage Cell Therapeutics LCTX $232M	107	-8	-7%	$113M
17	ATHX 17 DELISTED Athersys, Inc. Common Stock ATHX	104	+10	+11%	$52M
18	18 Fate Therapeutics FATE $232M	103	+13	+14%	$488M
19	19 DELISTED Adverum Biotechnologies ADVM	100	+4	+4%	$194M
20	20 uniQure QURE $1.45B	97	+28	+41%	$833M
21	BLCM 21 DELISTED Bellicum Pharmaceuticals, Inc. BLCM	96	+6	+7%	$189M
22	22 Abeona Therapeutics ABEO $249M	92	+4	+5%	$585M
23	ADAP 23 DELISTED Adaptimmune Therapeutics ADAP	86	+10	+13%	$663M
24	24 Cellectis CLLS $113M	86	+17	+25%	$319M
25	25 Lakefront Biotherapeutics American Depositary Shares LKFT $1.93B	79	-3	-4%	$698M